GlassScriptPhysician profile
Kathleen E Ellison
NPI 1134516271
$7,782.43
in general payments reported to CMS, 2019-2025
28 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $907 · 2021: $225 · 2022: $995 · 2023: $3,516 · 2024: $1,634 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.25 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,071.55 | 2020-2024 | Tremfya, Simponi, Remicade |
| Pfizer INC. | $1,012.61 | 2019-2024 | |
| Abbvie INC. | $786.22 | 2019-2024 | |
| Leo Pharma INC. | $637.45 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $627.71 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $591.26 | 2020-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $518.62 | 2019-2024 | Aklief, Epsolay, Oracea |
| Genzyme Corporation | $413.08 | 2020-2024 | |
| Dermavant Sciences, INC. | $325.75 | 2023-2024 | Vtama |
| Lilly USA, LLC | $280.83 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $185.18 | 2023-2024 | |
| Almirall LLC | $171.27 | 2019-2023 | Klisyri |
| Sun Pharmaceutical Industries INC. | $151.47 | 2020-2023 | Winlevi, Absorica Ld |
| Allergan, INC. | $128.12 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $113.99 | 2019-2023 | Duobrii, Arazlo, Jublia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $105.80 | 2023 | Cimzia |
| Encore Dermatology INC. | $105.51 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $102.93 | 2023-2024 | Zoryve |
| Amgen INC. | $92.02 | 2023 | Enbrel, Otezla |
| E.R. Squibb & Sons, L.L.C. | $69.71 | 2022-2023 | Sotyktu |
| Epi Health, LLC | $60.12 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $56.03 | 2023-2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $50.32 | 2020 | |
| Mayne Pharma Commercial LLC | $31.29 | 2020 | |
| Convatec INC. | $25.76 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.63 | 2024 | Spevigo |
| Strata Skin Sciences, INC. | $22.60 | 2024 | Xtrac |
| Medimetriks Pharmaceuticals, INC. | $19.60 | 2023 | Clindacin Etz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.